These compounders boomed in recent years, especially as GLP-1 weight-loss drugs became so popular that they were deemed to be in shortage
Here, I review this remarkable development from the earliest observations of glucose lowering and modest weight losses with native glucagon-like peptide (GLP)-1 and short acting compounds, to the recent development of highly active formulations and new molecules
Robert Ashley, MD, is an internist and assistant professor of medicine at the University of California, Los Angeles
Shared Goal, Different Machinery Because both compounds are studied for the same outcome substantial weight loss it is tempting to treat them as interchangeable
A medical consultation is required before starting any peptide protocol.
Our promise : No judgment, no BS, just honest medical care from people who understand the job